Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Glecirasib PK in Healthy Subjects
NCT05875493Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glecirasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Area under plasma concentration (AUC) 0 to infinity at 31 days, Area under plasma concentration (AUC) 0 to t at 31 days and 1 more. Started May 2023; status: completed.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05875493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875493.